Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
1.055
-0.085 (-7.46%)
At close: Mar 28, 2025, 4:00 PM
1.087
+0.032 (3.00%)
After-hours: Mar 28, 2025, 6:00 PM EDT
Company Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Taylor Schreiber |
Contact Details
Address: 500 West 5th Street, Suite 1200 Austin, Texas 78701 United States | |
| Phone | 512 900 4690 |
| Website | shattucklabs.com |
Stock Details
| Ticker Symbol | STTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001680367 |
| CUSIP Number | 82024L103 |
| ISIN Number | US82024L1035 |
| Employer ID | 81-2575858 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Andrew R. Neill M.B.A. | Chief Financial Officer |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Conor Richardson CPA | Vice President of Investor Relations |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer |
| Casi DeYoung | Chief Business Officer |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs |
| George Fromm Ph.D. | Co-Chief Scientific Officer |
| Suresh de Silva Ph.D. | Co-Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 424B5 | Filing |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Dec 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 4, 2024 | 144 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |